Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F17%3A00011770" target="_blank" >RIV/75010330:_____/17:00011770 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/17:43913195 RIV/00216208:11130/17:10337709 RIV/00216208:11140/17:10337709 RIV/61989592:15110/17:73583821 a 2 dalších

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.13337/pdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/cen.13337/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/cen.13337" target="_blank" >10.1111/cen.13337</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas

Popis výsledku v původním jazyce

Objective: This study investigated whether gene expression levels of key modulators of the oxysterol signalling pathway modify the prognosis of patients with oestrogen receptor-positive (ER+) breast carcinomas via interaction with endocrine therapy. Context: The prognosis of patients with ER+ breast carcinoma depends on several factors. Previous studies have suggested that some oxygenated forms of cholesterol (oxysterols) bind to oestrogen receptor and anti-oestrogen binding site which may deregulate cholesterol homoeostasis and influence effect of therapy. Design: The expression levels of 70 oxysterol pathway genes were evaluated in a test set of breast carcinomas differing in ER expression. The genes differentially expressed in ER+ tumours were assessed in a comprehensive set of ER+ tumours to evaluate their clinical significance. Patients: A total of 193 primary patients with breast carcinoma were included. Measurements: The transcript levels were determined by quantitative real-time polymerase chain reaction. Results: The expression levels of 23 genes were found to be specifically dysregulated in ER+ tumours compared to ER-tumours of the test set. The expression levels of ABCG2, CYP7B1, CYP24A1, CYP39A1 and CH25H genes were found to be strongly associated with disease stage; however, none of the gene expression levels were associated with disease-free survival in patients treated with endocrine therapy. Conclusions: The expression of a number of oxysterol pathway genes is significantly modulated by ER expression and associated with the clinical stage of patients. However, the expression of oxysterol pathway genes was not found to modify the prognosis of ER+ patients with breast carcinoma treated with endocrine therapy.

Název v anglickém jazyce

Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas

Popis výsledku anglicky

Objective: This study investigated whether gene expression levels of key modulators of the oxysterol signalling pathway modify the prognosis of patients with oestrogen receptor-positive (ER+) breast carcinomas via interaction with endocrine therapy. Context: The prognosis of patients with ER+ breast carcinoma depends on several factors. Previous studies have suggested that some oxygenated forms of cholesterol (oxysterols) bind to oestrogen receptor and anti-oestrogen binding site which may deregulate cholesterol homoeostasis and influence effect of therapy. Design: The expression levels of 70 oxysterol pathway genes were evaluated in a test set of breast carcinomas differing in ER expression. The genes differentially expressed in ER+ tumours were assessed in a comprehensive set of ER+ tumours to evaluate their clinical significance. Patients: A total of 193 primary patients with breast carcinoma were included. Measurements: The transcript levels were determined by quantitative real-time polymerase chain reaction. Results: The expression levels of 23 genes were found to be specifically dysregulated in ER+ tumours compared to ER-tumours of the test set. The expression levels of ABCG2, CYP7B1, CYP24A1, CYP39A1 and CH25H genes were found to be strongly associated with disease stage; however, none of the gene expression levels were associated with disease-free survival in patients treated with endocrine therapy. Conclusions: The expression of a number of oxysterol pathway genes is significantly modulated by ER expression and associated with the clinical stage of patients. However, the expression of oxysterol pathway genes was not found to modify the prognosis of ER+ patients with breast carcinoma treated with endocrine therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30101 - Human genetics

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Endocrinology

ISSN

0300-0664

e-ISSN

1365-2265

Svazek periodika

86

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

852-861

Kód UT WoS článku

000403714100013

EID výsledku v databázi Scopus

—